Charles Schwab Investment Management Inc. Boosts Stock Position in Certara, Inc. (NASDAQ:CERT)

Charles Schwab Investment Management Inc. raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 1.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 699,575 shares of the company’s stock after acquiring an additional 12,720 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.43% of Certara worth $8,192,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Massachusetts Financial Services Co. MA increased its position in Certara by 40.7% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company’s stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the period. Landscape Capital Management L.L.C. acquired a new position in Certara during the 3rd quarter worth approximately $852,000. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in Certara during the 3rd quarter worth approximately $1,513,000. Quest Partners LLC acquired a new position in Certara during the 3rd quarter worth approximately $367,000. Finally, Zions Bancorporation N.A. increased its position in Certara by 18.5% during the 3rd quarter. Zions Bancorporation N.A. now owns 76,811 shares of the company’s stock worth $899,000 after purchasing an additional 11,995 shares during the period. 73.96% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Patrick F. Smith sold 5,409 shares of Certara stock in a transaction on Monday, October 7th. The shares were sold at an average price of $11.03, for a total value of $59,661.27. Following the completion of the sale, the insider now owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 2.39% of the company’s stock.

Certara Stock Up 0.8 %

NASDAQ:CERT opened at $11.60 on Wednesday. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of -57.55, a price-to-earnings-growth ratio of 5.45 and a beta of 1.53. Certara, Inc. has a one year low of $9.41 and a one year high of $19.87. The stock has a 50-day simple moving average of $10.82 and a 200 day simple moving average of $12.75. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The company had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same quarter in the previous year, the company posted $0.06 earnings per share. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. Sell-side analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Barclays lowered their price target on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a report on Thursday, November 7th. Robert W. Baird lowered their price target on Certara from $18.00 to $13.00 and set a “neutral” rating on the stock in a report on Tuesday, November 5th. Finally, UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a report on Friday, September 27th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.